Skip to content

Aberrant Gene Expression Prostate Carcinoma

Identification of Aberant Gene Expression in Human Prostatic Carcinoma

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00868803
Enrollment
5000
Registered
2009-03-25
Start date
1995-04-01
Completion date
2030-04-01
Last updated
2026-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate Cancer

Keywords

prostate cancer

Brief summary

The goal of the study is to gain a better understanding of the molecular changes responsible for causing prostate cancer and that examination of tissue and blood samples will help in the development of improved screening and therapeutic approaches.

Detailed description

The goal of this study is to identify novel genetic elements that are aberantly expressed throughout prostatic neoplastic progression. The approaches proposed exploit the known familial arm of prostatic cancer, using established molecular genetic approaches, and extend these studies to sporadic prostatic cancer using a novel technique of differential display. Application of the latter technique to colon cancer in the American population establishes this tumor type as a high priority for scientific investigation and this study is part of an initiative to address this problem. Presently the studies in the field of prostate are under-represented. The collection of tissue samples from patients diagnosed with prostate cancer. Patients will also provide a blood sample at the time of their surgery and potentially post-op from 6 mos to 5 years. Samples will also be obtained from patients who's biopsy turns out to be non-prostate cancer. These samples will be obtained shortly following the biopsy out to 6 months after the biopsy.

Interventions

None listed

Sponsors

Lahey Clinic
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
MALE
Healthy volunteers
Yes

Inclusion criteria

* Diagnosed prostate cancer undergoing prostatectomy * Suspicion of prostate cancer undergoing biopsy - negative biopsy * Health volunteer (control group) - blood sample for PSA

Exclusion criteria

* Patients not fitting the inclusion criteria

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORKimberly R Christ, PhD

Lahey Clinic

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 14, 2026